Globus Medical (GMED) Drops 5.58% on January 07

Equities Staff |

Globus Medical (GMED) was one of the Russell 2000's biggest losers for Thursday January 07 as the stock slid 5.58% to $26.05, a loss of $-1.54 per share. Starting at an opening price of $26.41 a share, the stock traded between $25.93 and $27.03 over the course of the trading day. Volume was 931,501 shares over 6,667 trades, against an average daily volume of 509,458 shares and a total float of 95.24 million.

The losses send Globus Medical down to a market cap of $2.48 billion. In the last year, Globus Medical has traded between $28.99 and $20.48, and its 50-day SMA is currently $26.19 and 200-day SMA is $25.25.

The stock has a P/E Ratio of 25.5.

Globus Medical Inc is a medical device company focused on developing products that promote healing in patients with musculoskeletal disorders.

Globus Medical is based out of Audubon, PA and has some 900 employees. Its CEO is David C. Paul.

For a complete fundamental analysis analysis of Globus Medical, check out’s Stock Valuation Analysis report for GMED. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Beleave Inc.

Beleave Inc is a biotech company. The Company is engaged in the production of medical marijuana under the Marihuana for Medical Purposes Regulations outlined by Health Canada.

Private Markets


Cloudera offers enterprises a new data platform built on the Apache Hadoop open-source software package. Hadoop is a data-management platform that can consolidate data in a single repository for comprehensive…

Santo Diablo Mezcal

Santo Diablo Mezcal has been created to capitalize on a boom sector of the beverage market currently full of many small unmemorable products by producing one sexy, household, easily recognizable…